.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED01_Crizotinib.Crizotinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED01_Crizotinib.Crizotinib| name: | Crizotinib |
| ATC code: | L01ED01 | route: | oral |
| n-compartments | 2 |
Crizotinib is an orally administered small-molecule inhibitor of ALK (anaplastic lymphoma kinase), ROS1, and MET tyrosine kinases used for the treatment of ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). It is approved for use in adults with advanced or metastatic NSCLC.
Population pharmacokinetics in adult cancer patients, oral administration, typical dose 250 mg twice daily, analyzed as a two-compartment model with first-order absorption.
Gibson, EG, et al., & Stewart, CF (2021). Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. Cancer chemotherapy and pharmacology 88(6) 1009–1020. DOI:10.1007/s00280-021-04357-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34586478
Gupta, N, et al., & Venkatakrishnan, K (2021). Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. Clinical pharmacokinetics 60(2) 235–247. DOI:10.1007/s40262-020-00929-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32816246
Greengard, E, et al., & Weigel, BJ (2020). Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer chemotherapy and pharmacology 86(6) 829–840. DOI:10.1007/s00280-020-04171-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33095287